TY - JOUR T1 - Beyond Deaths per Capita: Comparative CoViD-19 Mortality Indicators JF - medRxiv DO - 10.1101/2020.04.29.20085506 SP - 2020.04.29.20085506 AU - Patrick Heuveline AU - Michael Tzen Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/12/2020.04.29.20085506.abstract N2 - The number of CoViD-19 deaths is a lagged but more reliable indicator of the disease progression across populations than the number of confirmed cases. With substantial age and sex differences in CoViD-19 mortality, that number should be adjusted for the age-and-sex composition of the population as well as its total size. Following well-established practices in demography, this article discusses several period measures based on cumulative numbers of CoViD-19 deaths up to a point in time and illustrate them with weekly-updated data from 386 national and subnational populations. First is an unstandardized occurrence-exposure rate comparable to the Crude Death Rate. The peak estimate for New York exceeded the state most recent annual Crude Death Rate and remains the highest on record. Second, an indirectly standardized rate is shown to perform quite like a directly standardized rate but without requiring an age-and-sex breakdown of CoViD-19 deaths. Relative to the US, standardization lowers death rates in European populations and increases them in most other populations, with the highest standardized rates currently found in subnational Mexican and Peruvian populations. Last, projected end-of-the-year CoViD-19 death tallies can be translated into reductions in 2020 life expectancies, which could exceed two and a half years in Peru and Ecuador, and in various subnational entities from Baja California to Madrid and New York. To put these in perspective, the 1.5-year projected reduction for the US would bring 2020 life expectancy at birth to its lowest level since 2003 and induce its largest annual decline since World War II.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors benefited from facilities and resources provided by the California Center for Population Research at UCLA (CCPR), which receives core support (P2C-HD041022) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Publicly available data onlyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available online and can be accessed directly or through a web scraping routine that we provide at https://github.com/statsccpr/ind-cov-mort https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 https://covid19.healthdata.org/ https://www.cdc.gov/nchs/nvss/vsrr/COVID19/index.htm ER -